Pulmonary Hypertension

May 24, 2016May 24, 2016

Potential PAH Treatment Shows Promising Preclinical Results

Reviva Pharmaceuticals recently announced promising preclinical efficacy data for RP5063, a novel dopamine-serotonin modulator for pulmonary arterial hypertension (PAH), at the American Thoracic Society (ATS) 2016 International Conference in California. RP5063 is ... Read more

May 24, 2016May 24, 2016

Bayer Ends Phase 2 Trial of Riociguat in PH Patients with Idiopathic Interstitial Pneumonias

News, Pulmonary Hypertension

Bayer has stopped a Phase 2 clinical trial (NCT02138825) evaluating riociguat (Adempas) in patients with pulmonary hypertension associated with idiopathic interstitial pneumonias (PH-IIP) on the recommendation of the study’s Data Monitoring Committee (DMC). The committee — sometimes ... Read more

May 18, 2016May 18, 2016

Positive Interim Data for Pulmonary Hypertension Phase 2a Study Presented by Mast Therapeutics

News, Pulmonary Hypertension

Mast Therapeutics presented positive interim data from its Phase 2a clinical trial of the investigational drug AIR001 in patients with pulmonary hypertension (PH) associated with heart failure with preserved ejection fraction ... Read more

May 17, 2016May 25, 2016

Actelion’s Uptravi for PAH Granted Marketing Authorization by European Commission

News, Pulmonary Hypertension

The European Commission recently granted marketing authorization in the EU for Switzerland-based Actelion’s product Uptravi (selexipag) for the treatment of pulmonary arterial hypertension. PAH is a life-threatening disease characterized by abnormal constriction of the pulmonary ... Read more

May 16, 2016May 16, 2016

ATS 2016: Bayer Presents Data on Adempas for Pulmonary Hypertension

News, Pulmonary Hypertension

Bayer is presenting six abstracts at the American Thoracic Society (ATS) 2016 International Conference through May 18 in San Francisco, Calif. The presentations highlight the use of Adempas (riociguat) for pulmonary ... Read more

May 13, 2016May 13, 2016

ATS 2016 International Conference Features Keynote Series

COPD, Idiopathic Pulmonary Fibrosis, News, Pulmonary Hypertension

The American Thoracic Society (ATS) is hosting the ATS 2016 International Conference through May 18 in San Franscico, Calif. This year’s conference will feature the ATS Keynote Series with eight ... Read more

May 10, 2016May 11, 2016

Galectin Therapeutics Preclinical Research on Galectin-3 Role in PAH to be Presented at ATS 2016

News, Pulmonary Hypertension

Galectin Therapeutics, Inc., a biopharmaceutical company that develops therapeutic compounds that bind and inhibit galectin proteins with pathological activity, announced recently that its collaborative abstract on galectin-3 and its role ... Read more

May 9, 2016May 9, 2016

Insmed Incorporated to Present Data on Liposomal Technology To Treat PAH, IPF at 2016 American Thoracic Society Meeting

Asthma, News, Pulmonary Hypertension

Insmed Incorporated recently announced that it will present three ARIKAYCE™-related abstracts and one treprostinil prodrug abstract at the American Thoracic Society (ATS) 2016 International Conference in San Francisco, May 13-18. ARIKAYCE™ ... Read more

May 5, 2016May 5, 2016

AVEO Oncology Files Provisional Patent Applications for AV-353 for PAH Treatment

News, Pulmonary Hypertension

AVEO Oncology recently filed provisional patent applications with the United States Patent and Trademark Office (USPTO) covering composition of matter claims for AV-353, its Notch 3 inhibitory antibody. These are the ... Read more

May 4, 2016May 4, 2016

Pulmonary Arterial Hypertension May Be Treatable with Inhaled Gene Therapy

News, Pulmonary Hypertension

Researchers managed to halt the progression of pulmonary arterial hypertension (PAH) using a specific gene therapy approach in a pig model of the disease. The findings mean that in the future, ... Read more